This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
A drug which appears to directly inhibit testicular steroid synthesis is significantly effective in treatment of benign prostatic hypertrophy, according to investigators from the Albert Einstein College of Medicine, New York.
Reporting at the 113th Annual Convention of the American Medical Association in San Francisco in June, Jack Geller, MD, and associates detailed results of treating ten patients with 17-alpha hydroxy progesterone caproate (Delalutin).
The drug is known to inhibit testicular steroid synthesis in animals, and effectively substitutes for surgical castration in palliation of male breast cancer, they pointed out in explaining the rationale for treatment. In addition, it lacks intrinsic estrogenic or androgenic activity.
Although both estrogens and androgens have been used more or less unsuccessfully to treat benign prostatic hypertrophy for about 30 years, the investigators said they believed that secretion of testicular steroids was still implicated in the disease. They pointed out that: (1) benign prostatic hypertrophy
Progesterone Drug May Reduce Benign Prostatic Hypertrophy. JAMA. 1964;189(4):32. doi:10.1001/jama.1964.03070040098049